$545.00
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 0
● 18
▼ 0
IDXX: Lowering target price to $595.00
IDEXX Laboratories Earnings Preview: What to Expect
Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating
Overview
52-week range
$507
$770
14% of range
Avg surprise (last 3)
+4.2%
Avg reaction (last 2)
+4.5%
50% positive
Latest IV / EM
49%
EM ±11.3% · $540 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $3.47 | $3.42 | +1.5% | +17.2% | -0.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $3.40 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $3.63 | $3.31 | +9.7% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $2.96 | $2.92 | +1.4% | — | +9.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $2.80 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $2.44 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $2.81 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $2.53 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $2.67 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | BMO | $3.95 | $3.63 | +8.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14B | — | $1.11B | $1.11B | $998M | — | $976M | $1.00B |
| Cost of revenue | — | — | — | — | $375M | — | $380M | $384M |
| Gross profit | $723M | — | $683M | $695M | $623M | — | $596M | $619M |
| Operating income | $363M | — | $355M | $373M | $317M | — | $304M | $264M |
| Net income | $278M | — | $275M | $294M | $243M | — | $233M | $203M |
| EPS (diluted) | $3.47 | — | $3.40 | $3.63 | $2.96 | — | $2.80 | $2.44 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $201M | $180M | $208M | $165M | $164M | $288M | $309M | $402M |
| Inventory | $382M | $378M | $392M | $393M | $396M | $382M | $390M | $380M |
| Total current assets | $1.45B | $1.41B | $1.48B | $1.36B | $1.32B | $1.40B | $1.43B | $1.53B |
| Total assets | $3.39B | $3.35B | $3.39B | $3.33B | $3.21B | $3.29B | $3.35B | $3.41B |
| Long-term debt | $300M | $375M | $375M | $450M | $450M | $450M | $525M | $525M |
| Total liabilities | $1.83B | $1.75B | $1.83B | $1.87B | $1.77B | $1.70B | $1.73B | $1.83B |
| Total equity | $1.56B | $1.61B | $1.56B | $1.46B | $1.45B | $1.60B | $1.62B | $1.58B |